This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.
Medline price target raised to $55 from $50 at BTIG
BTIG analyst David Larsen raised the firm’s price target on Medline (MDLN) to $55 from $50 and keeps a Buy rating on the shares following the JP Morgan Healthcare Conference. The company provided a high-level overview for those who were new to the business, including highlights of its two key segments Medline Brand and Supply Chain Solutions, the analyst tells investors in a research note. BTIG is positive on the way Medline serves the entire healthcare continuum, and its Prime Vendor relationships are sticky, with a 98% retention rate.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDLN:
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
